The Pharmalot View

The Pharmalot View

Tweet this: Gottlieb’s leaving, and so is FDA’s highly effective communicator

By Ed Silverman

The Pharmalot View

Prepare for grilling: 7 questions for 7 pharma execs who’ll testify before Congress about prices

By Ed Silverman

The Pharmalot View

The military pushed it for the battlefield. The FDA went along. Is the newest opioid any better?

By Ed Silverman

The Pharmalot View

The list price is not right: Trump’s plan to force pharma to advertise prices is misguided

By Ed Silverman

The Pharmalot View

One of the world’s largest drug makers is paying docs again — and patients are the worse off

By Ed Silverman

The Pharmalot View

From zero to hero: J&J CEO praises Trump one year after chastising him

By Ed Silverman

The Pharmalot View

When modest is actually excessive: AstraZeneca spins its price hikes

By Ed Silverman

President Trump Delivers Remarks On Lowering Drug Prices In Rose Garden

The Pharmalot View

He can shame Pfizer and others, but Trump doesn’t have a practical way to lower drug prices

By Ed Silverman

The Pharmalot View

Novartis’ tone-deaf response to Michael Cohen: troubling, but not surprising

By Ed Silverman

The Pharmalot View

Sanofi scandal in the Philippines could spread dangerous mistrust of vaccines

By Ed Silverman

The Pharmalot View

The Pentagon wants to approve drugs for the battlefield. Here’s why that’s dangerous

By Ed Silverman

The Pharmalot View

California just passed a law to rein in drug prices. Here’s why it’s unlikely to make much difference

By Ed Silverman

The Pharmalot View

Here’s how a loophole in a transparency law can distort medical practices

By Ed Silverman

The Pharmalot View

This pharma CEO won praise for his ‘social contract’ with the public. But his latest move could shred that pledge

By Ed Silverman

The Pharmalot View

At $475,000, new cancer drug raises thorny questions about drug pricing — and value

By Ed Silverman

The Pharmalot View

Drug makers deserve to be publicly shamed for thwarting competition from generics

By Ed Silverman

The Pharmalot View

The art of the deal? Why a money-back guarantee for drugs is a bad idea

By Ed Silverman

The Pharmalot View

If drug companies are really ‘getting away with murder,’ Trump may be about to grant them a pardon

By Ed Silverman

The Pharmalot View

It’s time to make it legal for Americans to order prescription drugs from abroad

By Ed Silverman

The Pharmalot View

US taxpayers are funding a Zika vaccine. Let’s make sure US patients can afford it

By Ed Silverman

The Pharmalot View

The Trump administration could bring down drug prices. But it would take guts

By Ed Silverman

The Pharmalot View

Dear Scott Gottlieb: Add new warnings to Paxil labels. You may save a life

By Ed Silverman

The Pharmalot View

How a $37,000-a-year medicine sets a good model for drug pricing

By Ed Silverman

The Pharmalot View

Here’s one drug safety rule the FDA should enact — quickly

By Ed Silverman

The Pharmalot View

Dear Mr. President: Your view of the FDA is misguided. Here’s why

By Ed Silverman

The Pharmalot View

Grandstanding, not real change: Why drug prices in TV ads will be confusing and irrelevant

Kapoor certainly deserves to go to jail, but so do some other pharma execs

If the states don’t treat pharma as a utility, it may be ‘lights out’ for too many patients

Forget about an international pricing index for drugs. Cost-effectiveness is a better bargain

Tweet this: Gottlieb’s leaving, and so is FDA’s highly effective communicator

Prepare for grilling: 7 questions for 7 pharma execs who’ll testify before Congress about prices

The military pushed it for the battlefield. The FDA went along. Is the newest opioid any better?

The list price is not right: Trump’s plan to force pharma to advertise prices is misguided

One of the world’s largest drug makers is paying docs again — and patients are the worse off

From zero to hero: J&J CEO praises Trump one year after chastising him

When modest is actually excessive: AstraZeneca spins its price hikes

He can shame Pfizer and others, but Trump doesn’t have a practical way to lower drug prices

Novartis’ tone-deaf response to Michael Cohen: troubling, but not surprising

Sanofi scandal in the Philippines could spread dangerous mistrust of vaccines

The Pentagon wants to approve drugs for the battlefield. Here’s why that’s dangerous

California just passed a law to rein in drug prices. Here’s why it’s unlikely to make much difference

Here’s how a loophole in a transparency law can distort medical practices

This pharma CEO won praise for his ‘social contract’ with the public. But his latest move could shred that pledge

At $475,000, new cancer drug raises thorny questions about drug pricing — and value

Drug makers deserve to be publicly shamed for thwarting competition from generics

The art of the deal? Why a money-back guarantee for drugs is a bad idea

If drug companies are really ‘getting away with murder,’ Trump may be about to grant them a pardon

It’s time to make it legal for Americans to order prescription drugs from abroad

US taxpayers are funding a Zika vaccine. Let’s make sure US patients can afford it

The Trump administration could bring down drug prices. But it would take guts

Dear Scott Gottlieb: Add new warnings to Paxil labels. You may save a life

How a $37,000-a-year medicine sets a good model for drug pricing

Here’s one drug safety rule the FDA should enact — quickly

Dear Mr. President: Your view of the FDA is misguided. Here’s why

The Pharmalot View

Sign up for our Daily Recap newsletter